Singapore markets closed
Straits Times Index
3,297.55 -26.98 (-0.81%) Nikkei
38,814.56 +94.06 (+0.24%) Hang Seng
17,941.78 -170.82 (-0.94%) FTSE 100
8,146.86 -16.81 (-0.21%) Bitcoin USD
66,514.14 +285.82 (+0.43%) CMC Crypto 200
1,382.68 -35.19 (-2.48%)
AUPH Jun 2024 6.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:45PM EDT. Market open.
Loading interactive chart…
- Business Wire
Aurinia Announces 2024 Annual General Meeting Results
ROCKVILLE, Md. & EDMONTON, Alberta, June 14, 2024--Aurinia Announces 2024 Annual General Meeting Results
- Simply Wall St.
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now
Key Insights Aurinia Pharmaceuticals will host its Annual General Meeting on 14th of June CEO Peter Greenleaf's total...
- Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
ROCKVILLE, Md. & EDMONTON, Alberta, June 05, 2024--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with active
© 2024 Yahoo. All rights reserved.